| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
MCB-22-174 (0-40 μM) exhibits potent agonistic activity against Piezo1 in C3H10T1/2 cells, with an EC50 value of 6.28 μM [1]. MCB-22-174 (3-5 μM, 72 h) significantly upregulated the mRNA level of Runx2 in rMSCs and promoted osteogenic activity more effectively than Yoda1 [1]. MCB-22-174 (5 μM, 5-15 min) significantly upregulated the levels of p-ERK and p-CaMKII in rMSCs and activated the CaMKII/ERK signaling pathway more effectively than Yoda1 [1]. MCB-22-174 (5 μM) significantly reduced the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs, and its inhibitory effect on chondrogenesis and adipogenesis was more significant than that of Yoda1[1].
|
|---|---|
| ln Vivo |
MCB-22-174 (2 mg/kg (5 μmol/kg), administered intraperitoneally on days 1, 4, 7, 10 and 13) effectively improved bone quality in hindlimb unloading (HU) rats [1].
|
| Cell Assay |
Real-time quantitative PCR[1]
Cell Types: rMSCs Tested Concentrations: 3, 5 μM Incubation Duration: 72 hours Experimental Results: Runx2 mRNA levels were upregulated in rMSCs Western Blot analysis [1] Cell Types: rMSCs Tested Concentrations: 5 μM Incubation Duration: 5, 10, 15 minutes Experimental Results: p-ERK and p-CaMKII were upregulated in rMSCs |
| Animal Protocol |
Animal/Disease Models:Two-month-old SD rats were suspended by their hind limbs, with their tails fixed to the cage cover, so that their hind limbs were off the ground (the forelimbs were unaffected) to simulate a weightless state to induce disuse osteoporosis [1].
Doses: 2 mg/kg (5 μmol/kg) Route of Administration: Intraperitoneal injection on days 1, 4, 7, 10 and 13 Experimental Results: Improved bone quality in rats with disuse osteoporosis. Bone volume ratio (BV/TV) and trabecular thickness (Tb.Th.) were upregulated. Trabecular spacing (Tb.Sp.) was downregulated. Alkaline phosphatase (ALP) fluorescence area was increased. Promoted bone formation, with better effect than Yoda1. |
| References |
| Molecular Formula |
C16H14DCL2N5OS2
|
|---|---|
| Molecular Weight |
429.37
|
| CAS # |
3058199-58-6
|
| Appearance |
Off-white to light yellow solid
|
| SMILES |
ClC(C=CC=C1Cl)=C1C([2H])SC2=NN=C(C3=NC=C(NC[C@H](O)C)N=C3)S2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3290 mL | 11.6450 mL | 23.2899 mL | |
| 5 mM | 0.4658 mL | 2.3290 mL | 4.6580 mL | |
| 10 mM | 0.2329 mL | 1.1645 mL | 2.3290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
